Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their
growth. Drugs used in chemotherapy, such as flavopiridol, work in different ways to stop
cancer cells from dividing so they stop growing or die. Bortezomib may increase the
effectiveness of flavopiridol by making cancer cells more sensitive to the drug. Giving
bortezomib together with flavopiridol may kill more cancer cells. This phase I trial is
studying the side effects and best dose of bortezomib and flavopiridol in treating patients
with recurrent or refractory indolent B-cell neoplasms.